Mesoblast Limited (MSB) Price & Analysis

Compare

247 Followers

MSB Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$0.88 - AU$3.37

Previous CloseN/A

Volume5.54M

Average Volume (3M)5.08M

Market Cap

$2.38B

Enterprise ValueAU$713.46M

Total Cash (Recent Filing)$38.03M

Total Debt (Recent Filing)$126.11M

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Aug 27, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,277,782,200

10 Day Avg. Volume4,384,285

30 Day Avg. Volume5,083,161

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)1.05

Price to Sales (P/S)0.00

P/FCF Ratio-8.70

Enterprise Value/Market Cap0.30

Enterprise Value/Revenue29.55

Enterprise Value/Gross Profit-31.62

Enterprise Value/Ebitda-3.29

Forecast

1Y Price Target

$3.40

Price Target Upside89.10% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Mesoblast Limited News

PremiumThe Fly

Mesoblast gives update on Revascor accelerated approval, Ryoncil label extension

22h ago

MESO

PremiumThe Fly

Mesoblast gets years of orphan-drug exclusive approval from FDA for Ryoncil

29d ago

MESO

PremiumCompany Announcements

Mesoblast Advances FDA Approvals for Revascor® and Ryoncil®

1d ago

PremiumCompany Announcements

Vanguard Group Acquires Substantial Stake in Mesoblast Limited

7d ago

PremiumCompany Announcements

JPMorgan Becomes Substantial Holder in Mesoblast Limited

8d ago

PremiumCompany Announcements

Mesoblast Limited Announces Substantial Holding Update

10d ago

PremiumPre-Earnings

Is MEOBF a Buy, Before Earnings?

18d ago

PremiumCompany Announcements

Mesoblast Secures Seven-Year FDA Orphan-Drug Exclusivity for Ryoncil®

29d ago

See All AU:MSB News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

20.41% Insiders

2.45%

Mutual Funds

0.01% Other Institutional Investors

74.55% Public Companies and

Individual Investors

Detailed Ownership Overview >

MSB FAQ

What was Mesoblast Limited’s price range in the past 12 months?

Mesoblast Limited lowest share price was AU$0.88 and its highest was AU$3.37 in the past 12 months.

What is Mesoblast Limited’s market cap?

Mesoblast Limited’s market cap is $2.38B.

When is Mesoblast Limited’s upcoming earnings report date?

Mesoblast Limited’s upcoming earnings report date is Aug 27, 2025 which is in 75 days.

How were Mesoblast Limited’s earnings last quarter?

Currently, no data Available

Is Mesoblast Limited overvalued?

According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast Limited pay dividends?

Mesoblast Limited does not currently pay dividends.

What is Mesoblast Limited’s EPS estimate?

Mesoblast Limited’s EPS estimate is -0.05.

How many shares outstanding does Mesoblast Limited have?

Mesoblast Limited has 1,277,782,200 shares outstanding.

What happened to Mesoblast Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Mesoblast Limited?

Currently, no hedge funds are holding shares in AU:MSB

Mesoblast Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-21.31%

Trailing 12-Months

Asset Growth

-2.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mesoblast Limited

Mesoblast Limited (MSB) is a global leader in allogeneic cellular medicines for inflammatory diseases. The company operates primarily in the biotechnology and biopharmaceutical sectors, focusing on developing and commercializing innovative cellular therapies. Mesoblast's core products are based on its proprietary mesenchymal lineage cell technology platform, which aims to treat a broad range of severe and chronic conditions such as heart failure, chronic low back pain, and inflammatory bowel diseases.

MSB Company Deck

MSB Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant achievements, including the FDA approval of a key product and successful fundraising, alongside a strategic pipeline expansion. However, financial losses and dependency on future regulatory approvals present challenges. Overall, the sentiment reflects a positive outlook with caution about future regulatory and financial hurdles.Read More>

MSB Stock 12 Month Forecast

Average Price Target

AU$3.40

▲(89.10%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"AU$4","-1":"-AU$1","0.25":"AU$0.25","1.5":"AU$1.5","2.75":"AU$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.4000000012461,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$3.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4037179085,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$3.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4000000012461,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$3.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Sep<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.9969230770189306,2.1138461540378612,2.2307692310567924,2.347692308075723,2.4646153850946537,2.5815384621135844,2.6984615391325155,2.815384616151446,2.932307693170377,3.0492307701893075,3.1661538472082382,3.283076924227169,{"y":3.4000000012461,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.9972090698846152,2.1144181397692305,2.231627209653846,2.3488362795384616,2.466045349423077,2.5832544193076923,2.7004634891923076,2.817672559076923,2.9348816289615387,3.052090698846154,3.1692997687307694,3.2865088386153847,{"y":3.4037179085,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.9969230770189306,2.1138461540378612,2.2307692310567924,2.347692308075723,2.4646153850946537,2.5815384621135844,2.6984615391325155,2.815384616151446,2.932307693170377,3.0492307701893075,3.1661538472082382,3.283076924227169,{"y":3.4000000012461,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.076,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.033,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.384,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.295,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.995,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.935,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >